Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Timing of recombinant LH supplementation in POSEIDON group 2 patients under a GnRH antagonist IVF regimen
ChiCTR2200057208Phase 4Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of lutropin alfa and recombinant human follicle stimulating hormone in infertility (2 arms), sponsored by Peking University People's Hospital. Primary endpoint: persistent pregnancy rate. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
lutropin alfarecombinant human follicle stimulating hormone
03
Conditions
infertility
Beyond the preview
Go deeper on ChiCTR2200057208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200057208.